Cargando…

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland

BACKGROUND: A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared to doxorubicin alone. The recently presented phase III study of doxorubicin and olaratumab i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gennatas, Spyridon, Chamberlain, Florence, Carter, Thomas, Slater, Susanna, Cojocaru, Elena, Lambourn, Beth, Stansfeld, Anna, Todd, Radha, Verrill, Mark, Ali, Nasim, Jones, Robin L., Simmonds, Peter, Keay, Nicola, McCarty, Heather, Strauss, Sandra, Karavasilis, Vassilios, Dileo, Palma, Benson, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203838/ https://www.ncbi.nlm.nih.gov/pubmed/32391141 http://dx.doi.org/10.1186/s13569-020-00131-x

Ejemplares similares

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
por: Yonemori, Kan, et al.
Publicado: (2018)

Olaratumab’s failure in soft tissue sarcoma
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
por: Jones, Robin L., et al.
Publicado: (2018)

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model
por: Higuchi, Takashi, et al.
Publicado: (2019)

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
por: Villalobos, Victor M., et al.
Publicado: (2019)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
por: McGuire, William P., et al.
Publicado: (2018)

Phase I study of olaratumab in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma
por: Moore, Donald C., et al.
Publicado: (2018)

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
por: Davis, Elizabeth J, et al.
Publicado: (2017)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
por: Attia, Steven, et al.
Publicado: (2023)

Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
por: Pender, Alexandra, et al.
Publicado: (2017)

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
por: Mo, Gary, et al.
Publicado: (2017)

Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report
por: Xing, Tuo, et al.
Publicado: (2021)

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
por: Mascarenhas, Leo, et al.
Publicado: (2021)

Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts
por: Cornillie, Jasmien, et al.
Publicado: (2019)

Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic
por: Younger, Eugenie, et al.
Publicado: (2020)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

THE OCCURRENCE DURING ACUTE INFECTIONS OF A PROTEIN NOT NORMALLY PRESENT IN THE BLOOD : V. PHYSICAL-CHEMICAL PROPERTIES OF THE C-REACTIVE PROTEIN CRYSTALLIZED BY A MODIFIED TECHNIQUE
por: Wood, Harrison F., et al.
Publicado: (1954)

Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit
por: Cojocaru, Elena, et al.
Publicado: (2021)

Learning Red Hat Enterprise Linux and Fedora
por: McCarty, Bill, et al.
Publicado: (2004)

Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers
por: Smrke, Alannah, et al.
Publicado: (2020)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis
por: Carter, Thomas J., et al.
Publicado: (2020)

Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing’s and other Small Round Cell Sarcomas
por: Whelan, Jeremy, et al.
Publicado: (2012)

Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre
por: Chamberlain, Florence, et al.
Publicado: (2020)

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
por: Wagner, A. J., et al.
Publicado: (2017)

Current antimicrobial use in farm animals in the Republic of Ireland
por: Martin, Hannah, et al.
Publicado: (2020)

Calculator calculus
por: McCarty, George
Publicado: (1982)

Topology : an introduction with application to topological groups
por: McCarty, George
Publicado: (1988)

One hundred years of presidents of SAB/ASM: the Rockefeller connection.
por: McCarty, M.
Publicado: (1999)

Learning Red Hat Linux
por: McCarty, Bill
Publicado: (2003)

PURIFICATION AND PROPERTIES OF DESOXYRIBONUCLEASE ISOLATED FROM BEEF PANCREAS
por: McCarty, Maclyn
Publicado: (1946)

THE OCCURRENCE OF POLYGLYCEROPHOSPHATE AS AN ANTIGENIC COMPONENT OF VARIOUS GRAM-POSITIVE BACTERIAL SPECIES
por: McCarty, Maclyn
Publicado: (1959)

THE INHIBITION OF STREPTOCOCCAL DESOXYRIBONUCLEASE BY RABBIT AND HUMAN ANTISERA
por: McCarty, Maclyn
Publicado: (1949)

Cannot write session to /tmp/vufind_sessions/sess_bkk5hqu0thq3c7m0t4qrg25pjp